Basel Medical Group, Inc. (NASDAQ: BMGL) is a global medical device company specializing in the design, development and distribution of single-use interventional products for cardiovascular and vascular procedures. The company’s core portfolio encompasses guiding catheters, angioplasty accessories, sheath introducers and specialty devices used in minimally invasive diagnostics and interventions. Leveraging advanced materials and proprietary coating technologies, Basel Medical Group focuses on improving procedural efficiency and patient outcomes in catheter-based therapies.
Founded in 1994 and headquartered in Basel, Switzerland, Basel Medical Group has expanded its footprint across Europe, North America, Asia-Pacific and Latin America through a combination of in-house manufacturing and strategic partnerships. The company operates production facilities in Basel, Shanghai and Monterrey, Mexico, and maintains distribution networks in over 60 countries. In addition to its manufacturing capabilities, Basel Medical Group invests in state-of-the-art research and development centers to support continuous innovation in interventional cardiology, electrophysiology and peripheral vascular applications.
Over the years, Basel Medical Group has pursued targeted acquisitions and collaborative agreements to broaden its product offering and market reach. Notably, the 2018 acquisition of TechCath Biomed augmented the company’s electrophysiology portfolio with advanced mapping and ablation catheters. Under the leadership of Chief Executive Officer Dr. Peter Müller and Chief Financial Officer Isabella Chang, the company emphasizes clinical education and customer support, operating dedicated training facilities and online learning platforms for interventional specialists. By integrating cutting-edge technology with comprehensive procedural training, Basel Medical Group aims to address evolving clinical needs and reinforce its position in the global medical device arena.
AI Generated. May Contain Errors.
